Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Price & Analysis

Tonix Pharmaceuticals Holding Corp. (TNXP) fell 6.97% to USD 9.88 as of July 25, 2026 at 03:52 UTC, according to Nexqual real-time market data.

TNXP last closed at USD 10.62; the session ranged USD 9.81–10.66 on volume of 711,447 shares. Market capitalization is $157.50M, with a 52-week range of USD 9.81–69.97 (NMS). Source: Nexqual, July 25, 2026 at 03:52 UTC.

Key Statistics (as of July 25, 2026 at 03:52 UTC)

Technical Analysis (TNXP)

Nexqual's technical model rates TNXP "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:52 UTC.

Analyst Ratings (TNXP)

Wall Street analysts rate TNXP "Strong Buy" based on 5 analysts, with a mean price target of USD 42.2 (range USD 22–65), per Nexqual as of July 25, 2026 at 03:52 UTC.

Earnings (TNXP)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 03:52 UTC.

Financials & Fundamentals (TNXP)

Source: Nexqual, July 25, 2026 at 03:52 UTC.

Financial Health Score (TNXP)

Nexqual rates Tonix Pharmaceuticals Holding Corp.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:52 UTC.

Ownership (TNXP)

Source: Nexqual, July 25, 2026 at 03:52 UTC.

Leadership (TNXP)

Tonix Pharmaceuticals Holding Corp. is led by Seth Lederman (age 67), Co-Founder, President, CEO & Chairman, per Nexqual as of July 25, 2026 at 03:52 UTC.

Major Backers & Investors (TNXP)

Notable institutional backers of Tonix Pharmaceuticals Holding Corp. include Citadel, Jones Hill Capital LP, Balyasny Asset Management LP, according to Nexqual as of July 25, 2026 at 03:52 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 03:52 UTC.

From Tonix Pharmaceuticals Holding Corp.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

• Tonix Medicines is the only manufacturer with both a branded injectable and nasal spray indicated for the acute treatment of migraine with or without aura in adults.   Development Pipeline   Central Nervous System   In September 2025, we announced the successful completion of a Type B Pre-IND meeting with the FDA regarding the development of TNX-102 SL for the treatment of MDD.
• We complement our management team with a network of scientific, clinical, and regulatory advisors that includes recognized experts in their respective fields.   Our Strategy   Our strategy is to use our integrated development and marketing capabilities to advance innovative programs across multiple therapeutic areas through the drug development process, with the ultimate objectives of FDA approval and commercialization.
• We believe this will satisfy one of the criteria for approval in Japan and China and will allow us to reference the U.S. efficacy data to support marketing applications in those countries.    A Phase 1 PK study was initiated in March 2022 and the clinical phase was completed in May 2022.

Partnerships

• The DoD announced in December 2022 a plan to move beyond a "one bug, one drug" approach and is seeking broad-spectrum drugs as it may be hard to predict which or how many viruses may be deployed on the battlefield.   In July 2024, we were awarded a contract with a potential for up to $34 million over five years by DTRA.
• Tonix plans to initiate enrollment of the study in mid-year 2026.   TNX-102 SL – Acute Stress Disorder Program   TNX-102 SL is being developed as a bedtime treatment for ASR/ASD in collaboration with the University of North Carolina under an investigator-initiated IND.    Phase 2 OASIS Study   This investigator-initiated study is being conducted by the University of North Carolina Institute for Trauma Recovery.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:52 UTC. This page is informational and not investment advice.